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Abstract: Introduction: Efficient treatment of asthma can play an important role in controlling asthma attacks, rapid
recovery and decrease of patient mortality. Therefore, in the present study the therapeutic effect of low-dose
ketamine is evaluated in patients with acute asthma attack. Methods: In the present single-blind, randomized
clinical trial with placebo control, the effect of low-dose intravenous ketamine in treating 18 to 85 year-old asth-
matic patients who presented to the emergency department was evaluated. Peak expiratory flow rate (PEFR)
and the patients’ response to treatment were measured before and 1 hour after treatment. Additionally, using
SPSS 22.0, effectiveness of ketamine with 0.3, 0.4, and 0.5 mg/kg doses followed by infusion of the same dose
during 30 minutes were compared with placebo. Results: 92 patients were enrolled (59.8% female, mean age
48.5 ± 13.9 years). 15 (16.3%) patients were treated with 0.3 mg/kg ketamine, 14 (15.2%) with 0.4 mg/kg, and 16
(17.4%) with 0.5 mg/kg doses. Mean PEFR was 336.2 ± 101.5 liters in the placebo group and 345.8 ± 84.7 liters
in the ketamine group before intervention (p = 0.6), while after intervention, they were 352.1 ± 101.2 and 415.8
± 76.2 liters, respectively (p = 0.001). Ketamine treatment with 0.4 and 0.5 mg/kg doses led to a higher increase
in PEFR compared to 0.3mg/kg dose (df: 3, 88; F = 23.8; p < 0.001). Conclusion: It seems that administration of
0.4 - 0.5 mg/kg doses of intravenous ketamine followed by infusion of the same dose during 30 minutes can be
effective for rapid recovery of PEFR in patients with mild to moderate asthma.
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1. Introduction
A
sthma is a diffused obstruction of airways that may
present as shortness of breath, wheezing, and cough-
ing. It is one of the most common chronic illnesses,
which presently affects 300 million people all over the world
and this number is predicted to rise to 100 million in 2025
(1). In Iran, the average prevalence of this disease in the un-
der 18-year-old population is estimated to be 13.4% (2). Clin-
ical symptoms of asthma are relieved spontaneously or us-
ing drugs. Comprehensive research has been done on con-
trol and treatment of asthma and standard treatments have
been developed. Yet, a high percentage of patients do not re-
spond well to the treatments and might experience severe at-
tacks and dangerous complications such as hypoxia, respira-
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tory arrest, and mortality. A bunch of controlling or preven-
tive drugs such as steroids, inhaled beta agonists and anti-
cholinergics, and short-acting theophylline are suggested for
management of the patients (3). Ketamine is a well-known
drug with safe and predictable sedative, analgesic, and anti-
emetic effects. The half-life of this drug is 2-4 hours and it
is rapidly absorbed, crosses blood-brain barrier, and exerts
its effect on central nervous system (CNS) (5). It is also a
bronchodilator, and using a 1-2 mg/kg dose of it has been
approved as an inductive agent in rapid sequence intubation
(RSI) of asthma patients (4). It protects airways and respira-
tory reflexes without any disturbances to the cardiovascular
system. Therefore, it may be prescribed in emergency de-
partments with limited monitoring devices. The important
thing about this drug is that in doses lower than 1mg/kg it
does not have sedative effects, while in higher doses it can
cause side effects such as apnea and laryngospasm. These
side effects can be severe in 1-2% of patients and are very
dose-dependent and more probable in higher doses and in-
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travenous (IV) prescription (6). Using 1-2 mg/kg IV doses fol-
lowed by 2-3 mg/kg IV infusion has been able to delay the
need for intubation in pediatric asthma attack (7). Intro-
ducing new ways for controlling asthma attack with the aim
of rapid recovery, decreasing cost, and discharging patients
from emergency department seems necessary from thera-
peutic and logistic viewpoints. Therefore, the present study
aims to evaluate the effect of low-dose ketamine in treatment
of patients with acute asthma attack.
2. Methods
2.1. Study design and setting
The present study is a single blind, randomized clinical trial
with placebo control that evaluates the effect of low-dose ke-
tamine in treating asthmatic patients who presented to the
emergency department of Al-Zahra teaching Hospital, Isfa-
han, Iran, during January to August 2016. Informed written
consent was obtained from all patients included in the study.
In addition, the present study was approved by the Ethics
Committee of Isfahan University of Medical Sciences. The
researchers adhered to the principles of Helsinki Declaration
and patient data confidentiality. This study has been regis-
tered on Iranian Registry of Clinical Trials (IRCT) under the
number IRCT2015102912072N9.
2.2. Participants
Patients with mild to moderate asthma (table 1), aged be-
tween 18 to 85 years old, without any prohibition for us-
ing IV ketamine and history of allergic reaction, were in-
cluded. If the patient’s clinical condition worsened during
the study, or needed ventilator support for respiration or
showed ketamine side effects, he/she would be excluded.
Non-randomized, convenience sampling was done and pa-
tients were randomly allocated to intervention (IV ketamine)
and control (placebo) groups using block randomization.
2.3. Intervention:
All patients underwent pulse oximetry and constant moni-
toring of arterial oxygen saturation, as well as oxygen therapy
if needed. Both groups received basic treatments of asthma
attack with standard doses including inhaled beta agonists
and anticholinergics, and IV corticosteroids. The interven-
tion group received IV ketamine with 0.3, 0.4, or 0.5 mg/kg
doses in addition to the standard treatment. Since ketamine
is colorless and odorless and its appearance is like water, dis-
tilled water was used as placebo for the control group. IV
ketamine vials were 10 cc in volume with 50 mg/cc concen-
tration (made by ROTEXMEDICA Company, Germany). At
the time of use, drug was drawn in a syringe based on the
patient’s weight and the volume was then set to 5 cc using
distilled water. Its injection was done during 1-2 minutes
in a peripheral vein. Subsequently, the same dose was in-
fused during 30 minutes. Peak expiratory flow rate (PEFR)
was measured and recorded before and 1 hour after treat-
ment for all patients. The method for determining PEFR was
as follows: first, the device was set at 0, then it was held in
a horizontal state and the patient was asked to hold the de-
vice’s pipe, which was washed and disinfected before, with
their lips in a manner that air could only pass through the
pipe. They were then asked to forcefully blow their expira-
tory flow into the peak flow meter (SIBEL, Spain) after a deep
inhalation. Finally, the indicator would show a number rep-
resenting the peak expiratory flow. The peak expiratory flow
for each patient was then compared to their expected natu-
ral flow based on their sex, age, and height, and if it was lower
than 70% of the normal rate, the case was considered as acute
asthma attack. The peak flow meter number was read and re-
ported by one person, for all patients. Response to treatment
was determined based on PEFR an hour after treatment ini-
tiation and was rated as good (PEFR > 70%), partial (40% <
PEFR < 69%), and poor (PEFR < 40%) (table1).
2.4. Data gathering
A senior emergency medicine resident was responsible for
data gathering using a check list that consisted of demo-
graphic data (sex, age), possible side effects of ketamine, and
PEFR of patients before and 1 hour after intervention.
2.5. Statistical Analysis
The sample size calculated for this study was 60 cases con-
sidering Zα =1.96, Zβ = 0.84, S = 59, d = 30. Data were en-
tered to SPSS 22.0. After making sure data distribution was
normal using Kolmogorov–Smirnov test (p = 0.62), they were
presented as mean and standard deviation for quantitative
data and frequency and percentage for qualitative data. In-
dependent t-test was used for comparison of PEFR between
the ketamine and placebo groups. In addition, to evaluate
the efficiency of various ketamine doses (0.3, 0.4, 0.5 mg/kg)
one-way ANOVA was used. In all tests, p < 0.05 was consid-
ered significant.
3. Results
92 patients were enrolled (59.8% female, mean age 48.5 ±
13.9 years). 47 (51.1%) of the patients were in the placebo
group and 45 (48.9%) in the ketamine group. 15 (16.3%) pa-
tients were treated with 0.3 mg/kg ketamine, 14 (15.2%) with
0.4 mg/kg, and 16 (17.4%) with 0.5 mg/kg doses. Age distri-
bution between the studied groups was not significantly dif-
ferent (p = 0.09) but sex distribution significantly differed (p
= 0.01). Since patient’s sex is entered in the formula for cal-
culation of PEFR, this difference in distribution is adjusted
for the analyses. Mean PEFR was 336.2 ± 101.5 liters in the
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Table 1: Definitions and measurement
PEFR * PEFR was measured using a peak flow meter and the normal rate
varies a little based on sex, age, and height of
the patient
Asthma attack Acute attack: PEFR < 70%
Mild to moderate attack: 40% < PEFR < 69%
Severe attack: PEFR < 40%
Response to treatment Good response: PEFR > 70%
Partial response: 40% < PEFR < 69%
Poor response: PEFR < 40%
Apnea Oxygen saturation dropping to < 85% for at least 3 seconds or de-
crease in respiratory rate to < 8 /minute
*: Peak expiratory flow rate.
Table 2: Comparing mean change in peak expiratory flow rate (PEFR) in different groups
Group PEFR Change P*
Before After
Placebo 336.2 ± 101.5 352.1 ± 101.2 16.0 ± 30.5 Ref
0.3 mg/kg ketamine 325.3 ± 48.1 367.3 ± 56.9 42.0 ± 23.0 0.17
0.4 mg/kg ketamine 396.4 ± 89.4 443.6 ± 67.9 52.9 ± 45.0 0.02
0.5 mg/kg ketamine 320.6 ± 91.9 431.9 ± 80.2 111.3 ± 62.8 < 0.001
*, significance level has been reported based on comparison with the placebo group. Data were presented as mean ± standard deviation.
placebo group and 345.8 ± 84.7 liters in the ketamine group
before intervention (p = 0.6), while after intervention, they
were 352.1 ± 101.2 and 415.8 ± 76.2 liters, respectively (p =
0.001). Treatment with low-dose ketamine has significantly
increased PEFR compared to placebo (p < 0.0001). PEFR be-
fore intervention was not significantly different between the
placebo group and different ketamine dose groups (df: 3, 88;
F = 2.2; p = 0.1). However, ketamine treatment with 0.4 mg/kg
(p = 0.02) and 0.5 mg/kg (p < 0.001) doses led to a significant
increase in PEFR compared to placebo. PEFR changes in the
0.3 mg/kg dose group did not differ from the placebo group
(df: 3, 88; F = 23.8; p = 0.17) (table 2). Side effects of ketamine
were not observed in any of the patients.
4. Discussion
The findings of the present study reveal that treatment of
asthma with low-dose ketamine increases PEFR. This rise is
significant in 0.4 and 0.5 mg/kg doses. 0.5 mg/kg dose had
higher efficiency compared to the 0.4 mg/kg dose.
As we have mentioned before, asthma is one of the most
common chronic illnesses all over the world. Based on the
involvement of the area, symptoms vary between a wheez-
ing sound to airway obstruction. Severe asthma can lead to
respiratory deficiency and need for ventilator. Inhaled corti-
costeroids are among the drugs suggested for asthma treat-
ment in children and adults (8-11). To open the bronchial
airways in asthmatic patients, ketamine may also be help-
ful. The first effective use of this drug in relieving pediatric
asthma has been reported about 30 years ago (12). In var-
ious studies, ketamine has been suggested as an inductive
agent for endotracheal intubation in asthma patients due to
its benefits for bronchial airway stabilization. Its serial injec-
tion will provide better results (4, 13-17). Ketamine increases
respiratory rate and subsequently, oxygen pressure, and de-
creases CO2 pressure, which leads to asthma symptom relief
(18). Its most important probable side effects include halluci-
nation, agitation, apnea, and laryngospasm (6). In a study by
Huber et al., after ketamine prescription a two third increase
in airway stability was reported (19). In a study to evaluate
the effectiveness of ketamine in symptom relief and pediatric
asthma indices, 1 mg/kg dose of ketamine on admission and
0.75 mg/kg dose during the first hour were intravenously ad-
ministered and the patients’ vital signs, PEFR, and clinical
asthma score were evaluated. The results showed that in all
the afore-mentioned indices, after IV ketamine administra-
tion, asthma symptoms were relieved (17). In a clinical trial
by Howton et al. IV administration of low-dose ketamine with
0.2 mg/kg dose and repeated injection of 0.5 mg/kg dose 3
times per hour in patients over 18 years old, had a significant
effect on respiratory rate, respiratory flow, and Berg’s score of
asthmatic patients compared to the placebo group. While in
a similar study with the same initial dose and twice a day in-
jection with 0.5 mg/kg dose, asthmatic children’s condition
did not significantly improve (20). The effect of low- dose ke-
tamine in adults who were not ventilator-dependent showed
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that this drug is generally effective for relieving bronchial
airway spasms and increasing blood oxygen saturation, al-
though in some cases it will be accompanied by side effects
such as hallucination, agitation and increase in pulmonary
secretions (16). Some have reported ketamine to be the drug
that makes asthmatic children independent of mechanical
ventilators (7). Based on the findings of this study, it seems
that administration of 0.4 and 0.5 mg/kg doses of ketamine
can have beneficial effects in asthma symptom relief com-
pared to the placebo group.
5. Limitation
The present study had some limitations such as small num-
ber of patients in each group of ketamine doses, which makes
interpretation and generalization of the results difficult. Fur-
ther study on the subject with a larger number of participants
and more accurate methodology is suggested to make the
findings more generalizable.
6. Conclusion
It seems that administration of 0.4 - 0.5 mg/kg doses of IV
ketamine followed by infusion of the same dose during 30
minutes can be effective for rapid recovery of PEFR in mild
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